This proposal is focused upon the molecular mechanism by which vasculopathy leads to fibrotic and autoimmune manifestations of systemic sclerosis. Autoantibodies generated by patients with systemic sclerosis are uniquely targeted to nucleolar proteins such as DNA topoisomerase I (topo-I). It has been demonstrated that topo-I is a substrate for protease(s) specific to the apoptotic process, resulting in novel cleavage fragments that may reveal cryptic epitopes to which the host has not previously been tolerized. It has also been recently demonstrated that several of the autoantigens targeted in diffuse scleroderma are uniquely susceptible to cleavage by metal-catalyzed oxidation reactions similar to what may occur during ischemia-reperfusion in the presence of appropriate metals. This process may also reveal immunocryptic epitopes and provides a molecular explanation for why certain proteins are uniquely targeted by the immune response in systemic sclerosis. However, it is well known that a cryptic epitope alone is not sufficient to generate autoreactivity, which also requires the participation of a molecular adjuvant, and uptake of the potential autoantigen by an antigen presenting cell (APC) with costimulatory capacity. The central hypothesis of this proposal is that chronic ischemia-reperfusion injury in patients with systemic sclerosis not only generates immunocryptic epitopes within nucleolar autoantigens of cutaneous origin, but it also generates complement ligands that provide the molecular adjuvant required to break immune tolerance.
The specific aims of this proposal are to: 1) Determine the capacity of apoptotic blebs bearing complement ligands to modulate the cytokine expression and costimulatory capacity of antigen presenting cells, 2) characterize the immune responses to self antigen- containing apoptotic blebs, and 3) examine the role of complement ligand C3d during induction of autoreactive T and B cell responses to topo I in vitro. Although systemic sclerosis is the focus of this proposal, the data generated by these studies should provide insight into our understanding of vasculopathic and autoimmune processes in general.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR046764-02
Application #
6171627
Study Section
Special Emphasis Panel (ZAR1-AAA-B (O2))
Program Officer
Gretz, Elizabeth
Project Start
1999-09-27
Project End
2004-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
2
Fiscal Year
2000
Total Cost
$262,500
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kao, Amy H; McBurney, Christine A; Sattar, Abdus et al. (2014) Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 5:510-8
Kao, Amy H; Navratil, Jeannine S; Ruffing, Margie J et al. (2010) Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 62:837-44
Mehta, Nidhi; Uchino, Ken; Fakhran, Saeed et al. (2008) Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 39:3236-41
Lee, Chin; Almagor, Orit; Dunlop, Dorothy D et al. (2007) Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 34:2018-23
Piao, Wenhua; Liu, Chau-Ching; Kao, Amy H et al. (2007) Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus. J Rheumatol 34:1506-13
Navratil, Jeannine S; Manzi, Susan; Kao, Amy H et al. (2006) Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 54:670-4
Navratil, Jeannine S; Liu, Chau-Ching; Ahearn, Joseph M (2006) Apoptosis and autoimmunity. Immunol Res 36:3-12
Calano, Sarah J; Shih, Pei-An B; Liu, Chau-Ching et al. (2006) Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers. Adv Exp Med Biol 586:381-90
Lee, C; Almagor, O; Dunlop, D D et al. (2006) Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 45:53-60
Liu, Chau-Ching; Manzi, Susan; Kao, Amy H et al. (2005) Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Arthritis Rheum 52:3087-99

Showing the most recent 10 out of 18 publications